Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Robert Timmerman MD
The primary objective of the study is to determine whether radiotherapy involving high biological dose with limited treatment volume (using SBRT techniques) achieves acceptable primary tumor control (i.e., = >90% at 2 years) in operable patients with early-stage NSCLC.
Data for this trial is being collected via the NRG/RTOG Data Center.
Patients with T1, T2 (<= 5 cm), T3 (<= 5 cm), N0, M0 operable non-small cell lung cancer; patients with T3 tumors must have chest wall primary tumors only; no patients with tumors of any T-stage in the zone of the proximal bronchial tree. Patients with T3 tumors based on mediastinal invasion or < 2 cm toward carina invasion are not eligible.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.